Bone: Incretin hormones perceiver or receiver?

Experimental Diabetes Research

Volumn 2012, Issue , 2012, Pages

  Dicembrini, Ilaria ^a   Mannucci, Edoardo ^b   Rotella, Carlo Maria ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Careggi Teaching Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; PEPTIDE YY; PLACEBO; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; HORMONE; PROTEINASE INHIBITOR;

BONE METABOLISM; BONE TURNOVER; DRUG MECHANISM; FRACTURE; HORMONE RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; WEIGHT REDUCTION; ANIMAL; BIOLOGICAL MODEL; BONE; BONE DEVELOPMENT; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG POTENTIATION; FEMALE; MALE; METABOLISM; OSTEOLYSIS;

ANIMALS; BONE AND BONES; BONE RESORPTION; CLINICAL TRIALS AS TOPIC; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FRACTURES, BONE; HORMONES; HUMANS; INCRETINS; MALE; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOGENESIS; PROTEASE INHIBITORS; RECEPTORS, GLUCAGON;

EID: 84863663100     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2012/519784     Document Type: Review

References (42)

1. Henriksen D. B., Alexandersen P., Bjarnason N. H., Vilsbll T., Hartmann B., Henriksen E. E., Byrjalsen I., Krarup T., Holst J. J., Christiansen C., Role of gastrointestinal hormones in postprandial reduction of bone resorption Journal of Bone and Mineral Research 2003 18 12 2180 2189 (Pubitemid 37463311)
2. Clowes J. A., Hannon R. A., Yap T. S., Hoyle N. R., Blumsohn A., Eastell R., Effect of feeding on bone turnover markers and its impact on biological variability of measurements Bone 2002 30 6 886 890 (Pubitemid 34616018)
3. Bjarnason N. H., Henriksen E. E. G., Alexandersen P., Christgau S., Henriksen D. B., Christiansen C., Mechanism of circadian variation in bone resorption Bone 2002 30 1 307 313 (Pubitemid 34044332)
4. Clowes J. A., Khosla S., Eastell R., Potential role of pancreatic and enteric hormones in regulating bone turnover Journal of Bone and Mineral Research 2005 20 9 1497 1506 (Pubitemid 41243538)
5. Dicembrini I., Pala L., Rotella C. M., From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy Exp Diabetes Res 2011 2011 8
6. Walsh J. S., Henriksen D. B., Feeding and bone Archives of Biochemistry and Biophysics 2010 503 1 11 19
7. Khazai N. B., Beck G. R., Umpierrez G. E., Diabetes and fractures: an overshadowed association Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 6 435 445
8. Janghorbani M., Van Dam R. M., Willett W. C., Hu F. B., Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture American Journal of Epidemiology 2007 166 5 495 505 (Pubitemid 47283633)
9. Takiishi T., Gysemans C., Bouillon R., Mathieu C., Vitamin D and diabetes Endocrinology and Metabolism Clinics of North America 2010 39 2 419 446
10. Grey A., Bolland M., Gamble G., Wattie D., Horne A., Davidson J., Reid I. R., The peroxisome proliferator-activated receptor- agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial Journal of Clinical Endocrinology and Metabolism 2007 92 4 1305 1310 (Pubitemid 46556402)
11. Kahn S. E., Zinman B., Lachin J. M., Haffner S. M., Herman W. H., Holman R. R., Kravitz B. G., Yu D., Heise M. A., Aftring R. P., Viberti G., Rosiglitazone-associated fractures in type 2 diabetes: an analysis from ADOPT Diabetes Care 2008 31 5 845 851
12. Benvenuti S., Cellai I., Luciani P., Deledda C., Baglioni S., Giuliani C., Saccardi R., Mazzanti B., Dal Pozzo S., Mannucci E., Peri A., Serio M., Rosiglitazone stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells Journal of Endocrinological Investigation 2007 30 9 RC26 RC30
13. Nicodemus K. K., Folsom A. R., Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women Diabetes Care 2001 24 7 1192 1197 (Pubitemid 33716397)
14. Monami M., Cresci B., Colombini A., Pala L., Balzi D., Gori F., Chiasserini V., Marchionni N., Rotella C. M., Mannucci E., Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study Diabetes Care 2008 31 2 199 203 (Pubitemid 351213319)
15. Bonds D. E., Larson J. C., Schwartz A. V., Strotmeyer E. S., Robbins J., Rodriguez B. L., Johnson K. C., Margolis K. L., Risk of fracture in women with type 2 diabetes:the women's health initiative observational study Journal of Clinical Endocrinology and Metabolism 2006 91 9 3404 3410 (Pubitemid 44402111)
16. Ganji V., Zhang X., Tangpricha V., Serum 25-hydroxyvitamin D concentrations and prevalence estimates of hypovitaminosis D in the U.S. population based on assay-adjusted data Journal of Nutrition 2012 142 3 498 507
17. Mathieu C., Van Der Schueren B. J., Vitamin D deficiency is not good for you Diabetes Care 2011 34 5 1245 1246
18. Chung M., Balk E. M., Brendel M., Ip S., Lau J., Lee J., Lichtenstein A., Patel K., Raman G., Tatsioni A., Terasawa T., Trikalinos T. A., Vitamin D and calcium: a systematic review of health outcomes Evidence Report/Technology Assessment 2009 183 1 420
19. Vilsbll T., Krarup T., Deacon C. F., Madsbad S., Holst J. J., Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients Diabetes 2001 50 3 609 613 (Pubitemid 32195226)
20. Mannucci E., Ognibene A., Cremasco F., Bardini G., Mencucci A., Pierazzuoli E., Ciani S., Fanelli A., Messeri G., Rotella C. M., Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus Diabetic Medicine 2000 17 10 713 719
21. Holst J. J., The physiology of glucagon-like peptide 1 Physiological Reviews 2007 87 4 1409 1439 (Pubitemid 350041474)
22. Knudsen L. B., Madsen L. W., Andersen S., Almholt K., De Boer A. S., Drucker D. J., Gotfredsen C., Egerod F. L., Hegelund A. C., Jacobsen H., Jacobsen S. D., Moses A. C., Mlck A. M., Nielsen H. S., Nowak J., Solberg H., Thi T. D. L., Zdravkovic M., Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486
23. Yamada C., Yamada Y., Tsukiyama K., Yamada K., Udagawa N., Takahashi N., Tanaka K., Drucker D. J., Seino Y., Inagaki N., The murine glucagon-like peptide-1 receptor is essential for control of bone resorption Endocrinology 2008 149 2 574 579 (Pubitemid 351159357)
24. Hirsch P. F., Baruch H., Is calcitonin an important physiological substance? Endocrine 2003 21 3 201 208 (Pubitemid 37193984)
25. Pacheco-Pantoja E. L., Ranganath L. R., Gallagher J. A., Wilson P. J. M., Fraser W. D., Receptors and effects of gut hormones in three osteoblastic cell lines BMC Physiology 2011 11, article 12
26. Bollag R. J., Zhong Q., Phillips P., Min L., Zhong L., Cameron R., Mulloy A. L., Rasmussen H., Qin F., Ding K. H., Isales C. M., Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors Endocrinology 2000 141 3 1228 1235 (Pubitemid 32260466)
27. Sanz C., Vzquez P., Blzquez C., Barrio P. A., Alvarez M. D. M., Blzquez E., Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow American Journal of Physiology 2010 298 3 E634 E643
28. Villanueva-Peacarrillo M. L., Delgado E., Trapote M. A., Alcantara A., Clemente F., Luque M. A., Perea A., Valverde I., Glucagon-like peptide-1 binding to rat hepatic membranes Journal of Endocrinology 1995 146 1 183 189
29. Nuche-Berenguer B., Portal-Nez S., Moreno P., Gonzlez N., Acitores A., Lpez-Herradn A., Esbrit P., Valverde I., Villanueva-Peacarrillo M. L., Presence of a functional receptor for GLP-1 in osteoblastic cells, independent of the cAMP-linked GLP-1 receptor Journal of Cellular Physiology 2010 225 2 585 592
30. Nuche-Berenguer B., Moreno P., Esbrit P., Dapa S., Caeiro J. R., Cancelas J., Haro-Mora J. J., Villanueva-Peacarrillo M. L., Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states Calcified Tissue International 2009 84 6 453 461
31. Nuche-Berenguer B., Moreno P., Portal-Nuez S., Dapa S., Esbrit P., Villanueva-Peacarrillo M. L., Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states Regulatory Peptides 2010 159 13 61 66
32. Nuche-Berenguer B., Lozano D., Gutiérrez-Rojas I., Moreno P., Marioso M. L., Esbrit P., Villanueva-Peacarrillo M. L., GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia Journal of Endocrinology 2011 209 2 203 210
33. Ding K. H., Shi X. M., Zhong Q., Kang B., Xie D., Bollag W. B., Bollag R. J., Hill W., Washington W., Mi Q. S., Insogna K., Chutkan N., Hamrick M., Isales C. M., Impact of glucose-dependent insulinotropic peptide on age-induced bone loss Journal of Bone and Mineral Research 2008 23 4 536 543 (Pubitemid 351501894)
34. Wortley K. E., Garcia K., Okamoto H., Thabet K., Anderson K. D., Shen V., Herman J. P., Valenzuela D., Yancopoulos G. D., Tschp M. H., Murphy A., Sleeman M. W., Peptide YY regulates bone turnover in rodents Gastroenterology 2007 133 5 1534 1543 (Pubitemid 350029744)
35. Blonde L., Klein E. J., Han J., Zhang B., Mac S. M., Poon T. H., Taylor K. L., Trautmann M. E., Kim D. D., Kendall D. M., Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes Diabetes, Obesity and Metabolism 2006 8 4 436 447 (Pubitemid 44349236)
36. Riedt C. S., Cifuentes M., Stahl T., Chowdhury H. A., Schlussel Y., Shapses S. A., Overweight postmenopausal women lose bone with moderate weight reduction and 1g/day calcium intake Journal of Bone and Mineral Research 2005 20 3 455 463 (Pubitemid 40293494)
37. Bunck M. C., Eliasson B., Cornér A., Heine R. J., Shaginian R. M., Taskinen M. R., Yki-Jrvinen H., Smith U., Diamant M., Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes Diabetes, Obesity and Metabolism 2011 13 4 374 377
38. Bunck M. C., Poelma M., Eekhoff E. M., Schweizer A., Heine R. J., Nijpels G., Foley J. E.,Diamant M., Diamant M., Vildagliptin effects on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled, type 2 diabetes patients Journal of Diabetes 2012 4 2 181 185
39. Monami M., Dicembrini I., Antenore A., Mannucci E., Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials Diabetes Care 2011 34 11 2474 2476
40. Henriksen D. B., Alexandersen P., Hartmann B., Adrian C. L., Byrjalsen I., Bone H. G., Holst J. J., Christiansen C., Four-month treatment with GLP-2 significantly increases hip BMD. A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD Bone 2009 45 5 833 842
41. Gottschalck I. B., Jeppesen P. B., Hartmann B., Holst J. J., Henriksen D. B., Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome Scandinavian Journal of Gastroenterology 2008 43 11 1304 1310
42. Bardini G., Dicembrini I., Serio M., Rotella C. M., Vitamin D therapy in adults with diabetes mellitus Nature Reviews Endocrinology 2011 7 1 c1